Prof. Dr. Stefan Boes has been elected to the Executive Committee of the EuHEA (European Health Economics Association) on 10 July 2020 for an initial term of office of three years.

Kathryn Dawson-Townsend won the SSPH+ "Best published PhD Article Award” 2020.

Given the recent developments regarding the spread of COVID-19 the University of Lucerne will go digital as of March 16. The continuous functioning of the University is guaranteed. This includes research, teaching, executive education and administrative services.

Cancelled

The Lucerne Summer School in Health Econometrics aims to bring together PhD students and senior lecturers in applied health economics and econometrics to discuss recent developments in the field and exchange ideas in an informal setting.

Date: June 8-10, 2020

Im Rahmen der Generalversammlung des Universitätsvereins spricht Herr Prof. Dr. med. Gerold Stucki zum Thema "Entwicklung der Rehabilitation an der Universität Luzern".

How to improve the use of evidence-based health (care) information in practice and policy? The role of rapid reviews and policy briefs, and their synergistic effects.

The Institute of Social and Preventive Medicine, University of Lausanne, and the Department of Health Sciences and Health Policy, University of Lucerne, are jointly organising a workshop addressing how behavioural economics can help improve population health and health care delivery.

In this lecture series, international experts on rehabilitation will review the promise, and the challenges, of strenghtening rehabilitation in global health systems through collaborations with academic, governmental and non-governmental partners as well as the private sector.

Please note that lecture of Karl Blanchet, November 7 had to be cancelled!

The first conference of the Swiss Society of Health Economics will take place on September 14, 2018 at the University of Lucerne under the theme “Health Economics and Health System Reforms".

In this lecture series, professionals from industries, academia and patient organizations will share their visions how the patient perspective can become an integral part of the drug development process, and how this relates to public interests, regulatory requirements, the law and international initiatives.